The DOI matches its Crossref record; 10 of the 11 references it cites were found in a registry or an index.
Data on the in vitro and in vivo anti-tumor effects of itraconazole, paclitaxel, and the two in combination in HT-29 and YM-1 cancer cell line and HT-29 colon cancer xenograft models
Open accessAbstract
Colon cancer is one of the fatal cancers in the world that metastatic potential and resistance to chemotherapy drugs are outstanding causes of cancer-induced mortality [1], [2], [3], [4]. We have investigated in vitro and in vivo anti-cancer effect of itraconazole and paclitaxel alone and their anti-cancer synergistic effect through MTT assay in YM-1 and HT-29 cell lines and in HT-29 tumor-bearing nude mice. Histopathological experiment was done for further assessment. Also, we evaluated the inhibitory effect of itraconazole on P-gp using specific in vivo biodistribution through 99mTc-MIBI uptake. 99mTc-MIBI, a myocardial perfusion imaging agent, is a useful radiotracer in diagnosis of some tumors and the liver and tumor accumulation of 99mTc-MIBI is changed by P-gp regulators [5], [6], [7], [8]. The data presented in this article are related to the research paper entitled “Itraconazole synergistically increases therapeutic effect of paclitaxel and 99mTc-MIBI accumulation, as a probe of P-gp activity, in HT-29 tumor-bearing nude mice”. We hope our preliminary data to be helpful to design the chemotherapy regimen schedule with Itraconazole and Paclitaxel.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In both in vitro and in vivo xenograft models, the data presented demonstrated experimental support for the possible anticancer effect of paclitaxel and ITZ, as well as the two in combination, in human colon cancer.”
From Itraconazole as a repurposed anti-cancer agent: focusing on synthesis, mechanisms of action and therapeutic insights (2026) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An overview of cancer multidrug resistance: a still unsolved problem
Lage, H. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8111-5 · Cited by 412
Nanayakkara, A. K., Follit, C. A., Chen, G., Williams, N. S., Vogel, P. D., & Wise, J. G. (2018) · Scientific Reports · doi:10.1038/s41598-018-19325-x · Cited by 294
Agrawal, M., Abraham, J., Balis, F. M., Edgerly, M., Stein, W. D., Bates, S. E., Fojo, T., & Chen, C. C. (2003) · PubMed · Cited by 135
Jekerle, V., Klinkhammer, W., Scollard, D. A., Breitbach, K., Reilly, R. M., Piquette‐Miller, M., & Wiese, M. (2006) · International Journal of Cancer · doi:10.1002/ijc.21827 · Cited by 70
Itraconazole targets cell cycle heterogeneity in colorectal cancer
Buczacki, S. J. A., Popova, S. A., Biggs, E. K., Koukorava, C., Buzzelli, J. N., Vermeulen, L., Hazelwood, L. D., Francies, H. E., Garnett, M. J., & Winton, D. J. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20171385 · Cited by 64
Wong, M., EVANS, S., Rivory, L. P., Hoskins, J. M., Mann, G. J., FARLOW, D. C., Clarke, C. L., Balleine, R. L., & Gurney, H. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.09.002 · Cited by 63
Effect of NF-κB inhibitors on the chemotherapy-induced apoptosis of the colon cancer cell line HT-29
Liu, T., LIU, D., Liu, J., Song, J.-T., Gao, S., Li, H., Hu, L., & Liu, B. (2012) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2012.647 · Cited by 31
Ghadi, M., Hosseinimehr, S. J., Amiri, F. T., Mardanshahi, A., & Noaparast, Z. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173892 · Cited by 17
Self-citationGuo, X.-Y., Wang, P., Du, Q.-G., Han, S., Zhu, S.-M., Lv, Y.-F., Liu, G.-S., & Hao, Z.-M. (2014) · Drug Research · doi:10.1055/s-0034-1375665 · Cited by 7
St. John’s Wort accelerates the liver clearance of technetium-99-sestamibi in rats
Mohammadinia, S., Abedi, S. M., & Noaparast, Z. (2018) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000000880 · Cited by 5
Self-citation
Cited by
Sorted by citations
Zhou, F. J., Peterson, T., Fan, Z., & Wang, S. F. (2023) · Nutrients · doi:10.3390/nu15183881 · Cited by 87
Kast, R. E., Alfieri, A., Assi, H. I., Burns, T. C., Elyamany, A. M., González‐Cao, M., Karpel‐Massler, G., Marosi, C., Salacz, M. E., Sardi, I., et al. (2022) · Cancers · doi:10.3390/cancers14102563 · Cited by 20
Molecular Imaging in Cancer Chemoresistance: What’s Brewing?
Urso, L., Uccelli, L., Boschi, A., Schillaci, O., & Filippi, L. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268967 · Cited by 5
Zhou, T., Hu, C., Liu, D., Duan, Y., & Zhang, Z. M. (2026) · Microsystem Technologies · doi:10.1007/s00542-026-06081-6 · Cited by 2
Marzi, M., Ghasemian, A., Ghanbariasad, A., Nournia, E., & Zarenezhad, E. (2026) · RSC Advances · doi:10.1039/d5ra09799a
Exploratory high-throughput screening of repurposed drugs for canine lymphoid malignancies
Nishida, M., Sakuma, H., Ishida, M., Daiku, E., Takamiya, M., Tomiyasu, H., Nakamura, S., & Tsukamoto, A. (2025) · BMC Veterinary Research · doi:10.1186/s12917-025-05053-8
Metadata
- Authors
- Ghadi, M., Hosseinimehr, S. J., Talebpour Amiri, F., Mardanshahi, A., & Noaparast, Z.
- Affiliations
- Mazandaran University of Medical Sciences (IR)
- Corresponding author
- Noaparast, Zohreh
- Venue
- Data in Brief
- Publisher
- Elsevier BV
- Published
- 2021-04
- Volume
- 35
- Pages
- 106862
- ISSN
- 2352-3409 (ISSN-L)
- PMC
- PMC7903292
- OpenAlex
- W3132061907
- Cited by
- 6
- References
- 11
- Citations by year
- 2026: 2 · 2025: 2 · 2023: 1 · 2022: 1
- Type
- data paper
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Data in Brief (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Mazandaran University of Medical Sciences
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- itraconazole, paclitaxel, colon cancer, drug synergy, P-glycoprotein, tumor xenografts, HT-29 cells, chemoresistance, anticancer activity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
